Alternative Antidepressant Treatment for Patients Unable to Take SSRIs

Primary Alternative: SNRIs (Venlafaxine or Duloxetine)

The American College of Cardiology is not mentioned, however, the guideline recommends venlafaxine specifically shows statistically better response rates than fluoxetine for depression with prominent anxiety symptoms, making it ideal when anxiety is a significant component 1
Allow 6-8 weeks for adequate trial at therapeutic doses before determining treatment failure, according to the guideline 1
SNRIs have 40-67% higher discontinuation rates due to adverse effects (particularly nausea and vomiting) compared to SSRIs, as stated in the guideline 1

Bupropion is preferred when patients have concerns about sexual dysfunction or weight gain, as it has the most favorable profile for both, according to the guideline 1
Bupropion works through noradrenergic and dopaminergic mechanisms rather than serotonergic pathways, making it mechanistically distinct from SSRIs, as mentioned in the guideline 1

Clomipramine is effective but has worse side effect profile than SSRIs and SNRIs, limiting its use to refractory cases, as stated in the guideline 2, 3
Never prescribe tricyclics to patients with suicidal ideation due to high lethality in overdose, according to the guideline 1
Tricyclics carry significant cardiovascular risks including hypertension, hypotension, and arrhythmias, as mentioned in the guideline 1

CBT or interpersonal therapy should be offered as first-line treatment when patients refuse all antidepressants, with efficacy equivalent to pharmacotherapy for moderate depression, according to the guideline 1
Combination treatment (CBT + medication) is superior to either alone for depression with anxiety, as stated in the guideline 1
CBT should consist of 10-20 sessions with exposure and response prevention components, as mentioned in the guideline 4, 5

First choice: Venlafaxine XR 75-225 mg daily (superior efficacy in severe depression and anxiety comorbidity), according to the guideline 1
Add CBT at any stage to improve outcomes beyond medication alone, as stated in the guideline 1
Reserve tricyclics for refractory cases only after multiple failures, and never in suicidal patients, according to the guideline 1

Assess treatment response at 4 weeks and 8 weeks using standardized depression rating scales, as mentioned in the guideline 1
Monitor for treatment-emergent suicidality, especially in first 1-2 weeks after initiation or dose changes, according to the guideline 1
Screen for adherence, side effects, and patient satisfaction at each follow-up, as stated in the guideline 1